C

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Watchlist Manager
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Watchlist
Price: 20.8 CNY -6.47% Market Closed
Market Cap: 21.4B CNY
Have any thoughts about
China Resources Double-Crane Pharmaceutical Co Ltd?
Write Note

China Resources Double-Crane Pharmaceutical Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

China Resources Double-Crane Pharmaceutical Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
C
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Total Receivables
ÂĄ3B
CAGR 3-Years
11%
CAGR 5-Years
6%
CAGR 10-Years
7%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Receivables
ÂĄ3.3B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Receivables
ÂĄ1.1B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
16%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Receivables
ÂĄ7.5B
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
10%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Receivables
ÂĄ13.2B
CAGR 3-Years
19%
CAGR 5-Years
11%
CAGR 10-Years
13%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Receivables
ÂĄ172.9m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

China Resources Double-Crane Pharmaceutical Co Ltd
Glance View

Market Cap
21.4B CNY
Industry
Pharmaceuticals

China Resources Double-Crane Pharmaceutical Co., Ltd. engages in the processing, manufacture, and sale of pharmaceutical, chemical, and biomedical raw materials. The company is headquartered in Beijing, Beijing and currently employs 11,029 full-time employees. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The firm's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The firm distributes its products mainly in domestic market.

Intrinsic Value
34.08 CNY
Undervaluation 39%
Intrinsic Value
Price
C

See Also

What is China Resources Double-Crane Pharmaceutical Co Ltd's Total Receivables?
Total Receivables
3B CNY

Based on the financial report for Sep 30, 2024, China Resources Double-Crane Pharmaceutical Co Ltd's Total Receivables amounts to 3B CNY.

What is China Resources Double-Crane Pharmaceutical Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
7%

Over the last year, the Total Receivables growth was 30%. The average annual Total Receivables growth rates for China Resources Double-Crane Pharmaceutical Co Ltd have been 11% over the past three years , 6% over the past five years , and 7% over the past ten years .

Back to Top